Federico Perez focuses on Microbiology, Klebsiella pneumoniae, Colistin, Internal medicine and Antibiotics. His biological study spans a wide range of topics, including Molecular epidemiology, Acinetobacter baumannii and Infection control. His biological study deals with issues like Carbapenem, which deal with fields such as Mortality rate.
In his research, Fosfomycin is intimately related to Tigecycline, which falls under the overarching field of Colistin. The study incorporates disciplines such as Pseudomonas aeruginosa, Gastroenterology and Pediatrics in addition to Internal medicine. His research in Antibiotics tackles topics such as Intensive care medicine which are related to areas like Klebsiella species, Hospitalized patients, Pharmacology and Antimicrobial chemotherapy.
His scientific interests lie mostly in Microbiology, Klebsiella pneumoniae, Internal medicine, Antibiotics and Carbapenem-resistant enterobacteriaceae. His Microbiology study incorporates themes from Pseudomonas aeruginosa and Acinetobacter baumannii. His Klebsiella pneumoniae study integrates concerns from other disciplines, such as Tigecycline, Intensive care medicine, Colistin and Meropenem.
His work in Internal medicine covers topics such as Bacteremia which are related to areas like Incidence and Meningitis. His Antibiotics research includes elements of Efflux and Virology. His Carbapenem-resistant enterobacteriaceae research integrates issues from Carbapenem resistant Klebsiella pneumoniae, Klebsiella, Epidemiology and Confidence interval.
Federico Perez spends much of his time researching Microbiology, Internal medicine, Antibiotics, Klebsiella pneumoniae and Drug resistance. His work on Multiple drug resistance, Colistin and Bacteremia as part of his general Microbiology study is frequently connected to Chemistry, thereby bridging the divide between different branches of science. His work deals with themes such as Tazobactam, Osteomyelitis and Ceftolozane, which intersect with Internal medicine.
The study incorporates disciplines such as Siderophore, Emergency medicine and Intensive care medicine in addition to Antibiotics. Federico Perez has researched Klebsiella pneumoniae in several fields, including Antimicrobial, Therapeutic drug monitoring and Aztreonam. His work carried out in the field of Drug resistance brings together such families of science as Veterinary medicine, Antibiotic resistance, Multilocus sequence typing and Polymyxin.
Microbiology, Ceftazidime/avibactam, Klebsiella pneumoniae, Drug resistance and Antibiotic resistance are his primary areas of study. His Microbiology study focuses mostly on Multiple drug resistance and Bacteremia. His Klebsiella pneumoniae study frequently draws parallels with other fields, such as Therapeutic drug monitoring.
His studies in Drug resistance integrate themes in fields like Veterinary medicine and Polymyxin. He has included themes like Transformation, Enterobacteriaceae and Multilocus sequence typing in his Antibiotic resistance study. His work deals with themes such as Internal medicine, Tazobactam and Empiric therapy, which intersect with Ceftazidime.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Global Challenge of Multidrug-Resistant Acinetobacter baumannii
Federico Perez;Andrea M. Hujer;Kristine M. Hujer;Brooke K. Decker.
Antimicrobial Agents and Chemotherapy (2007)
THE CONTINUING CHALLENGE OF ESBLS
Federico Perez;Andrea Endimiani;Andrea Endimiani;Kristine M. Hujer;Robert A. Bonomo;Robert A. Bonomo.
Current Opinion in Pharmacology (2007)
Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study
Belén Gutiérrez-Gutiérrez;Elena Salamanca;Marina de Cueto;Po-Ren Hsueh.
Lancet Infectious Diseases (2017)
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
David Van Duin;Judith J. Lok;Michelle Earley;Eric Cober.
Clinical Infectious Diseases (2018)
Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA
Andrea Endimiani;Andrea M. Hujer;Federico Perez;Christopher R. Bethel.
Journal of Antimicrobial Chemotherapy (2009)
Outbreak of Colistin-Resistant, Carbapenem-Resistant Klebsiella pneumoniae in Metropolitan Detroit, Michigan
Dror Marchaim;Teena Chopra;Jason M. Pogue;Federico Perez.
Antimicrobial Agents and Chemotherapy (2011)
Identification of a New Allelic Variant of the Acinetobacter baumannii Cephalosporinase, ADC-7 β-Lactamase: Defining a Unique Family of Class C Enzymes
Kristine M. Hujer;Nashaat S. Hamza;Andrea M. Hujer;Federico Perez.
Antimicrobial Agents and Chemotherapy (2005)
Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination
Federico Perez;Andrea Endimiani;Andrea Endimiani;Amy J. Ray;Brooke K. Decker.
Journal of Antimicrobial Chemotherapy (2010)
Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients.
Federico Perez;David Van Duin.
Cleveland Clinic Journal of Medicine (2013)
In Vitro Activity of Fosfomycin against blaKPC-Containing Klebsiella pneumoniae Isolates, Including Those Nonsusceptible to Tigecycline and/or Colistin
Andrea Endimiani;Andrea Endimiani;Gopi Patel;Kristine M. Hujer;Kristine M. Hujer;Mahesh Swaminathan.
Antimicrobial Agents and Chemotherapy (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: